SCHEMBL20601795

SCHEMBL20601795

O=C(O)c1ccc(NC(=O)c2cc(Cl)ccc2Cl)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.56
TAS1R1 Q7RTX1 1/20 0.56
TAS1R2 Q8TE23 1/20 0.56
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
RAB9A P51151 2/20 0.53
NPC1 O15118 1/20 0.53
HPGD P15428 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
ALDH1A1 P00352 3/20 0.52
LMNA P02545 1/20 0.52
MAPT P10636 1/20 0.52
PPARG P37231 2/20 0.51
NR1H4 Q96RI1 2/20 0.51
PPARD Q03181 1/20 0.51
PTGFR P43088 1/20 0.51
SERPINE1 P05121 4/20 0.50
PYGL P06737 1/20 0.50
TP53 P04637 1/20 0.49
KCNK2 O95069 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20601603 0.89 PYGL (0.54) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL22871249 0.86 PYGL (0.55) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL22871382 0.85 PYGL (0.49) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL20601659 0.79 HDAC8 (0.67) TAS1R3TAS1R1MEN1KMT2ASMN1; SMN2
SCHEMBL16148208 0.77 KCNMA1 (0.64) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL22871358 0.76 TAS1R3 (0.53) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL22871349 0.76 NPC1 (0.50) MEN1KMT2ARAB9ANPC1LMNA
SCHEMBL22871420 0.76 MAPT (0.76) ALDH1A1MAPTPPARGNR1H4PTGFR
SCHEMBL31238369 0.76 TAS1R3 (0.86) TAS1R3TAS1R1TAS1R2MEN1KMT2A
SCHEMBL15643309 0.75 ALDH1A1 (0.57) TAS1R3TAS1R1TAS1R2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120025312-A Benzazepine derivatives 大塚制药株式会社 2025-05-23 CN disclosed
US-20250051310-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2025-02-13 US disclosed
EP-4056557-B1 BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS OTSUKA PHARMA CO LTD (JP) 2023-11-22 EP disclosed
US-20230265073-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-08-24 US disclosed
US-11673878-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-06-13 US disclosed
US-20210078976-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-03-18 US disclosed
US-10889570-B2 Benzazepine derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
EP-3645513-A1 BENZAZEPINE DERIVATIVES Otsuka Pharmaceutical Co., Ltd. (JP) 2020-05-06 EP disclosed
CN-110891939-A Benzazepine derivatives 大塚制药株式会社 2020-03-17 CN disclosed
WO-2019004421-A1 BENZAZEPINE DERIVATIVES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078976-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B TAS1R3 1362/4885TAS1R1 1013/4885TAS1R2 998/4885
US-20230265073-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B TAS1R3 1362/4885TAS1R1 1013/4885TAS1R2 998/4885
US-11673878-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B TAS1R3 1362/4885TAS1R1 1013/4885TAS1R2 998/4885
US-20250051310-A1 BENZAZEPINE DERIVATIVES AVPR2, AVPR1A, AVPR1B TAS1R3 1965/4885TAS1R1 1422/4885TAS1R2 1458/4885
US-10889570-B2 Benzazepine derivatives AVPR2, AVPR1A, AVPR1B TAS1R3 1362/4885TAS1R1 1013/4885TAS1R2 998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.